ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical…
Significant round will enable the Company to advance ICT01, its lead anti-butyrophilin 3A antibody, to completion of randomized Phase II trialsSeries C adds global investors Earlybird,…